For rare cases of aCML with JAK2 V617F mutation (62, 187, 188), ruxolitinib, a JAK2 inhibitor approved by the FDA in intermediate- to high-risk MF and PV intolerant or resistant to HU, can be used (189, 190). This evidence concerns the gene JAK2 and acquired polycythemia vera.